Macomics
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
47 Little France Cres, Edinburgh, Midlot...Website
www.macomics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Macomics
Founded in 2019, based out of Edinburgh, United Kingdom, Macomics is developing precision medicines to modulate macrophages for the treatment of cancer at University of Edinburgh, internationally recognised leaders in macrophage biology. It is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages ('TAMs') towards the clinic. Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology. The new investment and planned Series A will enable the company to accelerate progress of its antibody programs towards the clinic, expand its portfolio, and further invest in its target discovery technology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Macomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Macomics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Macomics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Macomics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Macomics
Earning: See what the market has to say on Macomics recently announced quarterly report
Funding: Get notified immidiatlly once Macomics has new funding data
Product Launch: Get notified when Macomics launches new products
Macomics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Macomics
Find 3 more new buyers
Compare Similar Companies to Macomics
Compare insights from companies similar to Macomics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Macomics
<$5M
1-10
Private
$5.9M
2019
N/A
Company Profile Activity
Activity Insights
Macomics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Macomics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Macomics.
Macomics financials insights
Gather financial insights about Macomics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Unspecified
$5.9M
Macomics Tech Stack
A closer look at the technologies used by Macomics
See more technologies
Macomics News & Media
Macomics Announces Neurodegeneration and Neuroinflammation Applications of ENIGMAC Drug Discovery Platform
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in neurodegeneration and neuroinflammation applications.Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom and BELLINZONA, Switzerland, June 19, 2024 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered a scientific collaboration with Prof. Andrea Alimonti at IOR (Institute of Oncology Research), one of Switzerland’s leading research institutes.Macomics Announces Appointment of Simon Dew as New Chief Business Officer
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, June 10, 2024 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery has announced the appointment of Simon Dew in the newly created position of Chief Business Officer (CBO). He will be instrumental in advancing Macomics’ mission to develop first-in-class medicines targeting macrophage-driven diseases of high unmet medical need, in oncology and chronic inflammatory diseases.Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom and MILAN, Italy, May 13, 2024 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered a scientific collaboration with Prof. Massimiliano Pagani from the IFOM (the AIRC Institute of Molecular Oncology), one of Italy’s leading research institutes in Cancer Research.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Macomics
Sign Up For FreeTo access detailed company insights
Founded in 2019, based out of Edinburgh, United Kingdom, Macomics is developing precision medicines to modulate macrophages for the treatment of cancer at University of Edinburgh, internationally recognised leaders in macrophage biology. It is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages... Read More
